Former Life Technologies executive Paul Grossman has joined Telegraph Hill Partners as a venture partner. Grossman previously was head of global strategy and corporate development at Life Tech, and he also held the same position at Invitrogen. Before he joined Invitrogen, Grossman held a variety of leadership roles at Applied Biosystems, including as a research scientist and patent attorney, VP of intellectual property, and VP of strategy and business development.

Becton Dickinson has appointed Amit Bhalla to be VP of global strategy and development. In the role, Bhalla will work with the senior management team to develop BD's overall strategy. Bhalla joins BD from Citi, where he has been director of equity research for life science tools and medical technology since 2006. Before joining Citi, he was VP of equity research for emerging medical technology at Morgan Stanley, and a technical operations R&D associate at Johnson and Johnson.

Ardy Arianpour has joined Pathway Genomics as chief strategy officer, the company said this week.

Arianpour most recently was senior VP of business development at Ambry Genetics, and during his 13-year career in the biotech sector he also has worked in senior sales and business development roles at Clinical Data, Cogenics, and Eurogentec North America. In his new post, Arianpour will lead the San Diego-based company's global strategy, strategic planning, and partnership activities.

Kevin Shianna has left the New York Genome Center, where he was most recently deputy scientific director of sequencing operations. His role has been taken over by Soren Germer and Dayna Oschwald, who both joined the NYGC in early 2012 as sequencing program managers.

Follow this link:
Gene by Gene's Clinical, Research Arrays Exempt from New Myriad BRCA Testing Agreement

Comments are closed.